ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Clinical practice"

  • Abstract Number: 109 • 2020 Pediatric Rheumatology Symposium

    Incidence, Contributing Factors, and Impact of Diagnostic Delay in Juvenile Idiopathic Arthritis: Analysis of the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry

    Mei-Sing Ong1, Gordon Schiff 2 and Marc Natter 3 for the CARRA investigators, 1Harvard Medical School & Harvard Pilgrim Healthcare Institute, Boston, 2Harvard Medical School, Boston, 3Boston Children's Hospital, Boston

    Background/Purpose: While early treatment of patients with newly diagnosed juvenile idiopathic arthritis (JIA) is an area of active study, delayed diagnosis of JIA is poorly…
  • Abstract Number: 191 • 2020 Pediatric Rheumatology Symposium

    Utilization of Telemedicine in Pediatric Rheumatologic Care

    Rajdeep Pooni1 and Tzielan Lee 1, 1Stanford Children's, Palo Alto

    Background/Purpose: Telemedicine has the potential for improving access to care, particularly for pediatric patients with complex needs in remote or rural locations. Previous studies have…
  • Abstract Number: 302 • 2019 ACR/ARP Annual Meeting

    Clinical Impact of a Rheumatology Musculoskeletal Ultrasound Clinic at a U.S. Academic Center

    Sarah Chung1, Katherine Wysham 2, Elizabeth Jernberg 3, Ingeborg Sacksen 3, Scott Pollock 1 and Alison Bays 1, 1University of Washington Division of Rheumatology, Seattle, WA, 2Veterans Health Administration Puget Sound, Seattle WA, Seattle, 3University of Washington Division of Rheumatology, Seattle

    Background/Purpose: Routine use of musculoskeletal ultrasound (MSK-US) to aid in clinical decision-making for rheumatology patients is less common in the United States than in Europe,…
  • Abstract Number: 654 • 2019 ACR/ARP Annual Meeting

    Applying Systemic Lupus International Collaborating Clinics (SLICC) and Provisional ACR/EULAR Systemic Lupus Erythematosus Classification Criteria in a Cohort of Patients with Undifferentiated Connective Tissue Disease

    Kyle Drehmel1, Alan Erickson 1, Bryant England 2 and Michelene Hearth-Holmes 1, 1University of Nebraska Medical Center, Omaha, NE, 2VA Nebraska-Western IA Health Care System & University of Nebraska Medical Center, Omaha

    Background/Purpose: Undifferentiated Connective Tissue Disease (UCTD) describes the clinical scenario where a patient demonstrates characteristics of a connective tissue disease but does not meet criteria…
  • Abstract Number: 1530 • 2019 ACR/ARP Annual Meeting

    Real World Effectiveness of Secukinumab in Patients with Ankylosing Spondylitis: Findings from a Recent Cross Sectional Survey of Rheumatologists and Patients in Europe

    Uta Kiltz 1, Elizabeth Holdsworth2, Haijun Tian 3, Nicola Booth 4, Papa Anthony 5, Lina Helsche 6, Dorothy Keininger 6 and Philip G Conaghan 7, 1Rheumazentrum Ruhrgebiet/Ruhr University Bochum, Herne, Germany, Herne, Germany, 2Adelphi Real World, Manchester, England, United Kingdom, 3Novartis Pharmaceuticals Corporation, East Hanover, NJ, 4Adelphi Real World, Bollington, United Kingdom, 5Adelphi Real World, Macclesfield, England, United Kingdom, 6Novartis Pharma AG, Basel, Basel-Landschaft, Switzerland, 7Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds & NIHR Leeds Biomedical Research Centre, Leeds, United Kingdom

    Background/Purpose: Ankylosing spondylitis (AS) can lead to reduced physical functioning and quality of life.  Secukinumab has demonstrated clinical benefits in AS patients in clinical trials1-2.…
  • Abstract Number: 2461 • 2019 ACR/ARP Annual Meeting

    Clinical Presentation and Treatment of Oligoarticular Psoriatic Arthritis in Canada: High Frequency of Smaller Joint Involvement

    Alfred Cividino1, Denise Nicholson 2, Sherif Guindi 2, Jennifer Jelley 2, Anne-Julie Gaudreau 2 and Dafna Gladman 3, 1McMaster University's Faculty of Health Sciences, Hamilton, ON, Canada, 2Celgene Corporation, Summit, NJ, 3University of Toronto, Toronto, ON, Canada

    Background/Purpose: Oligoarticular disease in patients with psoriatic arthritis (PsA) is often underdiagnosed and undertreated. The goal of this study is to understand and identify current…
  • Abstract Number: 2524 • 2019 ACR/ARP Annual Meeting

    24-Month Outcomes Associated with Belimumab in Black/African-American Patients with Systemic Lupus Erythematosus in a Clinical Practice Setting in the United States

    Christopher Collins 1, Gail Kerr 2, Joan Von Feldt 3, Bernie Rubin 4, Arie Katz 3, Vanessa Castellano 5, Jake Chung 4 and Christopher Bell5, 1MedStar Washington Hospital Center, Department of Rheumatology, Washington, DC, 2Washington DC VA Medical Center, Georgetown and Howard Universities, Washington DC, DC, 3GSK, Philadelphia, PA, 4GSK, Phildelphia, PA, 5GSK, Research Triangle Park, NC

    Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by diverse clinical manifestations and organ damage accrual. Black/African-American (B/AA) race is associated with…
  • Abstract Number: 2720 • 2019 ACR/ARP Annual Meeting

    Implementation of an Evidence-based Transition Clinic in a Pediatric Rheumatology Academic Institution

    Rebecca Overbury1, John Bohnsack 2, CJ Inman 3, Sara Stern 3, Karen James 3, Daniel Clegg 3, Tracy Frech 4 and Aimee Hersh 3, 1Assisstant Professor, University of Utah, Salt Lake City, UT, 2University of Utah School of Medicine, Salt Lake City, UT, 3University of Utah, Salt Lake City, UT, 4Division of Rheumatology, University of Utah and Salt Lake VAMC, Salt Lake City, UT

    Background/Purpose: Transition from pediatric to adult rheumatology care is more likely to be successful if a transition program is in place. Previously successful interventions to…
  • Abstract Number: 2796 • 2019 ACR/ARP Annual Meeting

    The Association Between Omega-3 Supplementation and Disease Activity in a Rheumatoid Arthritis (RA) Observational Cohort

    Adel Andemeskel1, Vivi Feathers 1, Christine Iannaccone 1, Jing Cui 1 and Nancy Shadick 1, 1Brigham and Women's Hospital, Boston, MA

    Background/Purpose: Omega-3 supplementation is one of a few complementary and alternative medicine (CAM) therapies that has shown promise in improving RA symptoms through small, randomized…
  • Abstract Number: 2760 • 2018 ACR/ARHP Annual Meeting

    Clinical Outcomes of Patients with Giant Cell Arteritis Treated with Tocilizumab in Real-World Clinical Practice

    Sebastian H. Unizony1, Jinglan Pei2, Páris N. Sidiropoulos2, Jennie H. Best2, Christine Birchwood2 and John H. Stone3, 1Massachusetts General Hospital, Harvard Medical School, Boston, MA, 2Genentech, Inc., South San Francisco, CA, 3Rheumatology (Medicine), Massachusetts General Hospital, Harvard Medical School, Boston, MA

    Background/Purpose: Previously, the GiACTA study demonstrated the superiority of subcutaneous (SC) tocilizumab (TCZ) plus prednisone vs prednisone alone in achieving sustained glucocorticoid (GC)-free remission in…
  • Abstract Number: 2774 • 2018 ACR/ARHP Annual Meeting

    Treatment with Methotrexate and Risk of Ischemic Relapses in Patients with Giant Cell Arteritis in Clinical Practice

    Judit Font Urgelles1, Luis Rodriguez-Rodriguez2, Zulema Rosales Rosado1,2, Dalifer Freites Núñez2, Leticia Leon2, Inmaculada Morado1, Esperanza Pato Cour1, Juan A Jover Jover1, Benjamín Fernández-Gutiérrez1 and Lydia A Alcazar2, 1Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, 2Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain

    Background/Purpose: Clinical trials have shown the efficacy of Methotrexate (MTX) in giant cell arteritis (GCA) but it is necessary to corroborate these results in real…
  • Abstract Number: 2870 • 2018 ACR/ARHP Annual Meeting

    Thresholds for Disease Activity Measures DAS28, CDAI, and RAPID3 Do Not Align with Clinical Practice Patterns of Rheumatoid Arthritis (RA) Disease Management Decisions

    Brian C. Sauer1, Chia-Chen Teng, MS1, Neil A. Accortt2, David H. Collier2, Tzu-Chieh Lin2 and Grant W. Cannon1, 1Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, 2Amgen Inc., Thousand Oaks, CA

    Background/Purpose:   Treatment guidelines recommend using disease activity measures (DAMs) to guide RA therapy, but DAM use in real-world treatment decisions is not defined.  We…
  • Abstract Number: 524 • 2018 ACR/ARHP Annual Meeting

    Clinical Course of Interstitial Lung Disease in Rheumatoid Arthritis Patients in Clinical Practice

    Cristina Vadillo Font1, María A Nieto2, Dalifer Freites Núñez3, Zulema Rosales Rosado1,3, Leticia Leon3, Judit Font Urgelles1, Juan A Jover Jover1 and Lydia A Alcazar3, 1Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, 2Chest diseases, Hospital Clínico San Carlos, Madrid, Spain, 3Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain

    Background/Purpose: Interstitial lung disease (ILD) is the extra-articular manifestation that most frequently worsens the course of Rheumatoid arthritis (RA) disease. Purpose: To describe the characteristics…
  • Abstract Number: 2872 • 2018 ACR/ARHP Annual Meeting

    Variation in Predictors of Patient and Physician Defined Flares in Rheumatoid Arthritis

    Anna O'Connor1, Joshua Baker2, Bryant R. England3, Brian C. Sauer4, Grant W. Cannon5 and J. Steuart Richards6, 1Department of Rheumatology, University of Pittsburgh Medical Center, Pittsburgh, PA, 2Philadelphia VA Medical Center and University of Pennsylvania, Philadelphia, PA, 3Rheumatology, VA Nebraska-Western Iowa Health Care System & University of Nebraska Medical Center, Omaha, NE, 4Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, 5Division of Rheumatology, Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, 6Pittsburgh VA Medical Center and University of Pittsburgh, Pittsburgh, PA

    Background/Purpose: The identification of risk factors associated with flares in RA is challenging because of the use of different composite disease activity scores and a…
  • Abstract Number: 621 • 2018 ACR/ARHP Annual Meeting

    Practical Optimization of Methotrexate Dose Improves Disease Control of Rheumatoid Arthritis Despite Reduction or Discontinuation of Oral Glucocorticoids

    Shintaro Hirata1, Kei Araki1, Hiroki Kohno1, Kazutoshi Yukawa1, Tadahiro Tokunaga1, Tatsuomi Kuranobu1, Katsuhiro Oi1, Yusuke Yoshida1, Tomohiro Sugimoto1, Keisuke Oda1,2, Takaki Nojima1,3 and Eiji Sugiyama1, 1Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Japan, 2Hiroshima Clinic, Hiroshima, Japan, 3Nojima Internal Medicine Clinic, Hiroshima, Japan

    Background/Purpose: Short-term glucocorticoids (GCs) along with methotrexate (MTX) has been recommended for newly onset patients with rheumatoid arthritis (RA) in EULAR recommendation 2016. However, it…
  • 1
  • 2
  • 3
  • …
  • 8
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology